Geneious Prime Enterprise Licenses

The Centers for Disease Control and Prevention (CDC), under the Department of Health and Human Services, intends to award a sole-source firm fixed-price contract for Geneious Prime Enterprise Academic Yearly Subscription licenses. The government is procuring 200 seats of this software because it is an integral component of several validated CLIA test protocols that cannot be modified without significant time and cost investment. The CDC plans to solicit and negotiate exclusively with Graphpad Software LLC under the authority of FAR 13.106-1(b) (SAP), though this pre-solicitation notice invites interested vendors to demonstrate their capability and interest in responding to the requirement. The government will consider all quotations and responses received by the deadline solely for the purpose of determining whether to conduct a competitive procurement, and any decision not to compete will be at the government's sole discretion. Interested parties must submit their responses via email to the Contracting Officer at xur0@cdc.gov by 5:00 PM Eastern Time on December 16, 2025.

This procurement carries no set-aside designation and represents a sole-source approach intended for Graphpad Software LLC. The contract period of performance extends from February 23, 2026 through February 22, 2031, with four one-year option periods included. The notice does not disclose a specific award value or budget range for the 200-seat software licensing and support requirement. This is categorized as software licensing under NAICS 513210 (Software Publishers) and PSC 7A21 (IT and Telecom - Business Application Software with Perpetual License Software). The five-year base contract period combined with the four optional years provides the government with extended software licensing coverage while maintaining support services throughout the performance period.